3.435

1.63% 0.055

Pre-market: 3.40 -0.035 -1.02%

Processa Pharmaceuticals Inc (PCSA)

Overview News Price History Financials Discussions Forecast Stock Split

Processa Pharmaceuticals Inc stock is traded at $3.435, with a volume of 85,872. It is up +1.63% in the last 24 hours and down -50.58% over the past month. Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Previous Close:

$3.38

Open:

$3.5

24h Volume:

85,872

Relative Volume:

0.08

Market Cap:

$7.78M

Revenue:

Net Income/Loss:

$-12.88M

P/E Ratio:

-1.4796

EPS:

-2.3215

Net Cash Flow:

$-10.85M

1W Performance:

+19.27%

1M Performance:

-50.58%

6M Performance:

-29.10%

1Y Performance:

-85.54%

1-Day Range:

$3.40

$3.59

1-Week Range:

$2.82

$3.59

52-Week Range:

$2.7375

$23.25

Processa Pharmaceuticals Inc Stock (PCSA) Company Profile

Name

Processa Pharmaceuticals Inc

Sector

Healthcare (1115)

Industry

Biotechnology (620)

Phone

443-776-3133

Address

601 21ST STREET, SUITE 300, VERO BEACH

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

PCSA's Discussions on Twitter

Compare PCSA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PCSA Processa Pharmaceuticals Inc	3.435	7.66M	0	-12.88M	-10.85M	-2.3215
VRTX Vertex Pharmaceuticals Inc	484.15	118.84B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	812.27	81.61B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	422.50	53.69B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	822.94	49.49B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	176.00	37.34B	447.02M	-1.18B	-906.14M	-6.1812

Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-25-24	Initiated	H.C. Wainwright	Buy

Processa Pharmaceuticals Inc Stock (PCSA) Latest News

Jan 07, 2026

Processa Pharmaceuticals Regains Nasdaq Minimum Bid Compliance - TipRanks

Jan 07, 2026

Jan 06, 2026

Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pal-Item

Jan 06, 2026

Processa Pharmaceuticals completes enrollment for NGC-Cap breast cancer study - Investing.com Nigeria

Jan 06, 2026

Jan 05, 2026

Processa Pharmaceuticals completes enrollment of 20th patient in Phase 2 study - TipRanks

Jan 05, 2026

Processa Pharmaceuticals (PCSA) Advances in Phase 2 Cancer Study - GuruFocus

Jan 05, 2026

Processa Pharmaceuticals completes enrollment for NGC-Cap breast cancer study By Investing.com - Investing.com South Africa

Jan 05, 2026

Processa Pharmaceuticals Completes Patient Enrollment for Phase 2 Clinical Study of NGC-Cap in Advanced Breast Cancer, Interim Data Expected Q1 2026 - Quiver Quantitative

Jan 05, 2026

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study - The Manila Times

Jan 05, 2026

Jan 01, 2026